Comparative Longevity Industry Analysis and Classification Framework

Comparative Longevity Industry Analysis and Classification Framework

Coming soon

Aging Analytics Agency is currently producing a comprehensive proprietary analytical report on the Longevity Industry Comparative Analysis and Classification Framework (First Edition), featuring sophisticated, multidimensional analytical frameworks in order to identify the strongest players in the global Longevity Industry. We recognize that industry as complex and multidimensional as the Longevity industry requires the application of an equally multidimensional comparative analysis and classification framework. The analytical framework developed for this report applies specifically-designed metrics weighted in proportion to their importance to conduct ranking and benchmarking of leading industry players, technologies and scientific IP.

Aging Analytics Agency has, since its inception in 2013, been applying systematic methodologies to create different types of analytical frameworks that define and classify distinct scientific domains, technologies and applications very clearly, in a way that allows them to be quantitatively compared, and continually refining them to maintain their relevance against the changing dynamics of the industries they are applied to.

The company’s first efforts in this ongoing mission was the formulation of the ARMIF (Analytical Regenerative Medicine Industry Framework) classification system in 2013, which allowed companies active in the regenerative medicine industry to be clearly segregated and compared in terms of the scientific and technological strength of their product pipelines and R&D activities.

Since then, the company has continued to refine these comparative analysis systems, both in terms of the specific metrics used to conduct its market studies, as well as the mathematical formulas used to combine them, and the advanced visualization techniques used to make their forecasts, ranking and determinations maximally understandable.

Today, these analytical methodologies have evolved to incorporate 3-D frameworks where metrics and submetrics can be visualized simultaneously, as well as the development of “timeline machines” that allow the changing state of a company’s strength in specific areas ranging from scientific validation to business development, R&D, etc. to be visualized over time, and projected into the future based on the statistical properties of its past behaviour. These sophisticated analytical frameworks are now being applied to the Global Longevity Industry for the first time, enabling quantitative benchmarking of leading industry players and technologies.

Since investment in the biotechnology and life science sectors requires more technical expertise than other sectors to successfully assess the viability and achievability of new ventures, the potential for big fails and an ensuing bubble are greater. In the case of the BioTech industry, the failure rate for clinical trials is roughly 96%, and in the geroscience sector in particular, clinical trial failure rates approach 99% due to the complexity of the field, which will continue unless novel methods of assessment and due diligence are formulated and applied. In a similar vein, there is greater potential for over-promising or over-hyped ventures to receive large investments in place of ventures that are more realistic, don’t over-promise or over-hype their solutions. This trend also contributes to an economic climate that is more susceptible to growth rates beyond achievability and financial success, which, in turn, further exacerbates the potential for a bubble to form and burst.

If you or your institution is interested in purchasing access to this new proprietary report when it becomes available, please sign up to our private mailing list using the above subscription form, and we will contact you with further details.